Isabelle Ray‐Coquard
Université Claude Bernard Lyon 1(FR)European Organisation for Rare Diseases(FR)Université de Bordeaux(FR)Inserm(FR)Breast Cancer Research Foundation(US)Centre Hospitalier Universitaire de Grenoble(FR)Université de Poitiers(FR)Centre Léon Bérard(FR)Bordeaux Population Health(FR)Registre général des cancers de Lille et de sa région(FR)Health Services and Performance Research Laboratory(FR)Centre de Recherche en Cancérologie de Lyon(FR)Institut Bergonié(FR)Arcagy Gineco(FR)Eau de Paris (France)(FR)Research on healthcare performance(FR)
Publications by Year
Research Areas
Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, Sarcoma Diagnosis and Treatment, Uterine Myomas and Treatments, Endometrial and Cervical Cancer Treatments
Most-Cited Works
- → Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer(2019)1,962 cited
- → Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial(2017)1,842 cited
- → Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial(2014)1,598 cited
- → Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials(2009)1,581 cited
- → Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial(2016)1,190 cited
- → ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease